NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
    Nanobiotix to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
    Nanobiotix announces 18.1 month median overall survival for 41 evaluable elderly and frail patients with HNSCC in phase I expansion evaluating NBTXR3 as a single agent activated by radiotherapy

    ALL NANOBIOTIX PRESS RELEASES

    Events

    November 10, 2021

    SITC 2021

    More info
    November 16

    Jefferies London Healthcare Conference

    More info

    JOIN US


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer
     

    Download our latest
    Corporate Presentation

     
    English